???global.info.a_carregar???
João Trigueiro-Louro (JTL) is a Medical Doctor (NOVA Medical School), Pharmacist (Faculty of Pharmacy, Univesidade de Lisboa – FFUL, PT), PhD and Research Scientist, with a decade of experience in influenza and recent work on coronaviruses and flaviviruses. João is a physician practicing general medicine and emergency care at CUF Tejo and Hospital de São Francisco Xavier, ULSLO. He has ongoing experience in managing patients in Dedicated Areas for Respiratory Infections. He is closely connected with the pharmaceutical industry (2016–25), worked with Janssen Pharmaceuticals, Pfizer and Bayer on pharmacovigilance and regarding antimicrobial pipelines. Since 2015, JTL is a member of H. Rebelo-de-Andrade (HRA) Lab at Antiviral Resistance Lab, Infectious Diseases Department, National Institute of Health Dr. Ricardo Jorge (INSA), and at Host-Pathogen Interaction Unit, iMed.ULisboa, FFUL. He has been collaborating with HRA team in several projects with respect to the susceptibility of influenza virus and coronavirus to antiviral drugs; evolution of influenza viruses; molecular determinants of influenza pathogenesis; and exploring new antiviral compounds and influenza, coronavirus and flavivirus targets and their role on viral replication. In this field, JTL took an individual training at the Public Health England (Colindale,UK) with Dr. Angie Lackenby. JTL holds a PhD (2022) in Pharmacy – Microbiology, from the Programme in Medicines and Pharmaceutical Innovation (i3DU), FFUL - main subject: “Conserved proteins of influenza virus and coronavirus as emerging therapeutic targets” – with strong expertise in large sequence data treatment and analysis; in computational tools (e.g. machine learning) for structural characterization of viral targets; and on viral infection experiments. JTL is author and co-author of 10 (7 in the last 5 years) scientific publications/book chapters in the field of emerging pathogens; and presenter of dozens of oral communications at national and international meetings, winning two awards regarding best communication. During this period, JTL has also collaborated as volunteer consultant in the COVID-19 Task Force, General Directorate of Health (DGS-Lisbon); and has been co-supervisor of two Master Students at FFUL. JTL was also an invited teacher at Universidade Lusófona (in Public Health) and currently teaching at FFUL (Emerging Infections of Viral Etiology Course – Biopharmaceutical Sciences Master).
Read full resume ↓
Identification

Personal identification

Full name
João Trigueiro-Louro

Citation names

  • Trigueiro-Louro, João

Author identifiers

Ciência ID
4418-D8DC-249A
ORCID iD
0000-0003-0384-5319

Email addresses

  • joao.louro@insa.min-saude.pt (Professional)
  • jlouro@ulslo.min-saude.pt (Professional)

Addresses

  • Instituto Nacional de Saúde Doutor Ricardo Jorge, IP. Avenida Padre Cruz, 1649-016, Lisboa, Lisboa, Portugal (Professional)
  • Hospital de São Francisco Xavier, Estr. Forte do Alto Duque , 1449-005, Lisboa, Lisboa, Portugal (Professional)

Knowledge fields

  • Natural sciences - Biological Sciences - Virology
  • Medical and Health Sciences - Basic Medicine
  • Medical and Health Sciences - Clinical Medicine - General and Internal Medicine

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
English Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Spanish; Castilian Intermediate (B1) Intermediate (B1) Beginner (A1) Intermediate (B1)
German Beginner (A1) Beginner (A1) Beginner (A1) Elementary (A2) Beginner (A1)
Education
Degree Classification
2024 - 2024
Concluded
 Advanced Life Support Provider (Outros)
Unidade Local de Saúde de Lisboa Ocidental, Portugal
2017/01/01 - 2022/05/05
Concluded
 Doutoramento em Farmácia (Doutoramento)
Major in Microbiologia
Universidade de Lisboa Faculdade de Farmácia, Portugal

Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
"Conserved proteins of influenza virus and coronavirus as emerging therapeutic targets" (THESIS/DISSERTATION)
 Approved with Distinction and Honours
2022
Concluded
 Basic Life Support (Outros)
Centro Hospitalar de Lisboa Ocidental EPE, Portugal
2015/09/01 - 2021/06/01
Concluded
 Mestrado Integrado em Medicina (Mestrado integrado)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
 17
2020
Concluded
 TEAM (Trauma Evaluation and Management) Course (Outros)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
2017
Concluded
 Pharmacovigilance and Drug Safety Course (Outros)
Universidade de Lisboa Faculdade de Farmácia, Portugal
 17
2014
Concluded
 Integrated Masters in Pharmaceutical Sciences (Mestrado)
Universidade de Lisboa Faculdade de Farmácia, Portugal
"Susceptibility of influenza A virus to antiviral drugs. Targeting the NS1 dealer as a new anti-influenza virus strategy." (THESIS/DISSERTATION)
 16 (0-20 grading scale)
Affiliation

Science

Category
Host institution 		Employer
2015/02/14 - Current Researcher (Research) Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
2015/01/15 - Current Researcher (Research) Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2020 - 2021 Visiting Researcher (Research) Direção-Geral da Saúde, Portugal

Teaching in Higher Education

Category
Host institution 		Employer
2021 - 2025 Assistant (University Teacher) Universidade de Lisboa Faculdade de Farmácia, Portugal
2016/01/01 - 2019/12/01 Assistant Professor (University Teacher) Universidade Lusófona de Humanidades e Tecnologias, Portugal

Other Careers

Category
Host institution 		Employer
2022/01/01 - Current Interno (Médica) Unidade Local de Saúde de Lisboa Ocidental, Portugal
Unidade Local de Saúde de Lisboa Ocidental, Portugal

Others

Category
Host institution 		Employer
2024/08/01 - Current Physician - emergency care Hospital CUF Tejo, Portugal
Hospital CUF Tejo, Portugal
2024/05/02 - Current Consultant - Antifungal therapies Bayer Portugal SA, Portugal
2024/07 - 2024/08 Jury member in the AstraZeneca Scientific Medical Competition Nova Medical School, Portugal
2017/01/01 - 2022/02/28 Ph.D. fellow (FCT PD/BD/128402/2017) - Ph.D. Programme in Medicines and Pharmaceutical Innovation (i3DU). Tutor: Helena Rebelo-de-Andrade Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
2022 - 2022 Consultant - Pfizer - Antiviral Drugs for COVID-19 Pfizer Portugal, Portugal
2020 - 2021 Consultant in Virology - public health support (COVID-19 Task Force) - General Directorate of Health (DGS), Portugal Direção-Geral da Saúde, Portugal
2016/06/01 - 2016/12/30 Health Care Compliance Integrity Intern; antimicrobial pipeline Tutors: José Antunes (Medical director) and Ana Marta Cunha HCBIO) Janssen-Cilag Farmacêutica Lda, Portugal
2015/10/01 - 2016/06/30 Associate fellow (ref:2015DDI1232) Project:New antivirals and new brands: Phenotypic susceptibility profiles of influenza virus to the new NAIs and cost-efficient alternative solutions for neuraminida Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
2015/04/07 - 2015/09/30 Research grant holder Ref.PID/HPI/2015/002 Project: “Functional compatibility of the replication complex as a determinant of virulence in influenza for vaccine production”-FCT Tutors: Prof Dr. José Az Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2012/02/13 - 2014/12/15 Research student at Host-Pathogen Interaction Unit Advisor: Prof. Dr. Helena Rebelo de Andrade Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2014/06/02 - 2014/07/31 Curricular Training in a Hospital Supervisor: Dr. Margarida Freitas Hospital CUF Descobertas, Portugal
2014/03/03 - 2014/05/30 Research trainee within Public Health England Advisors: Dr. Angie Lackenby and Joanna Ellis Public Health England, United Kingdom
2013/09/02 - 2013/09/30 Scientific research at Department of Bioinorganic Chemistry. Advisor: Dr. Justyn Ochocki Uniwersytet Medyczny w Lodzi Wydzial Lekarski, Poland
Projects

Contract

Designation Funders
2023/02/01 - 2026 Delivering a Unified Research Alliance of Biomedical and public health Laboratories against Epidemics (DURABLE) Project no. 101102733
101102733
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Ongoing
2018/09/01 - 2021/08/31 Reverse Genetics Vaccine Seeds for Influenza: Mechanisms that drive the co-segregation of PB1 with antigenic proteins
PTDC/SAU-INF/30729/2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal

Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Concluded
2018/09/01 - 2021/07/31 Novel antivirals against Influenza: NS1 target validation and lead discovery
PTDC/QUI-OUT/32572/2017
Researcher
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal

Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal

Universidade de Coimbra Centro de Química de Coimbra, Portugal
Concluded
2013 - 2015 Functional compatibility of the replication complex as determinant of virulence in influenza viruses
PTDC/SAUMIC/122780/2010
Researcher
Fundação para a Ciência e a Tecnologia, Portugal
Concluded

Other

Designation Funders
2015 - 2015 Neuraminidase Inhibitors: new antivirals and new brands: Phenotypic susceptibility profiles of influenza virus to the new neuraminidase inhibitors and cost-efficient alternative solutions for neuraminidase activity and neuraminidase inhibition assay
2015DDI1232
Researcher
Instituto Nacional de Saúde Doutor Ricardo Jorge, Portugal
Concluded
2013 - 2015 Evaluation and characterization of the emergence of resistance to influenza antiviral drugs in the context of acute respiratory infection
FCG SDH49
Researcher
Fundação Calouste Gulbenkian, Portugal
Concluded
Outputs

Publications

Book chapter
  1. Trigueiro-Louro, João; Rebelo-de-Andrade, Helena. "Diagnóstico Laboratorial da Gripe". In Manual Sobre gripe, 125-170. lisboa, Portugal: Lidel, 2018.
    Published
Conference poster
  1. Filipe Almeida; Luís André Santos; Trigueiro-Louro, João; Helena Rebelo-de-Andrade. "Adaptive evolution of PB1 from A(H1N1)pdm09 towards an enhanced compatibility between PB1 and HA". Paper presented in Eighth ESWI Influenza and COVID-19 Conference 2021, 2021.
  2. Trigueiro-Louro, João; Figueiredo-Nunes, Inês; Santos, Luís A.; Almeida, Filipe; Correia, Vanessa; Guedes, Rita C.; Brito, Rui M.M.; Rebelo-de-Andrade, Helena. "Exploring influenza A and B therapeutics: NS1 as a potential universal antiviral target". Paper presented in The seventh ESWI Influenza Conference, Virtual Edition, 2020.
  3. Trigueiro-Louro, João; Santos, Luís A.; Almeida, Filipe; Correia, Vanessa; Brito, Rui M.M.; Rebelo-de-Andrade, Helena. "NS1 as a promising anti-influenza target: new putative druggable hot spots and their relevance on viral replication". Paper presented in The seventh ESWI Influenza Conference, Virtual Edition, 2020.
  4. Trigueiro-Louro, João; Correia, Vanessa; Figueiredo-Nunes, Inês; Gíria, Marta; Rebelo-de-Andrade, Helena. "Exploring coronavirus locks: Sequence-to-structure characterization of SARS-CoV-2, SARS-CoV and MERS-CoV proteins". Paper presented in The seventh ESWI Influenza Conference, Virtual Edition, 2020.
  5. Figueiredo-Nunes, Inês; Trigueiro-Louro, João; Correia, Vanessa; Gíria, Marta; Rebelo-de-Andrade, Helena. "Exploring antiviral strategies against a broad range of beta-CoVs: Spike and Polymerase proteins as promising anti-CoV targets". Paper presented in Special isirv-AVG Virtual Conference on ¿Therapeutics for COVID-19¿, 2020.
  6. Santos L.A.; Almeida F.; Trigueiro-Louro J.; Rebelo-de-Andrade H. "Cosegregation of influenza A A/H1N1pdm09 PB1 and glycoproteins HA and NA as a determinant factor for antigen yield". Paper presented in Seventh ESWI Influenza and COVID-19 Conference. Virtual Edition., 2020.
  7. Trigueiro-Louro, João. "PB1-HA functional compatibility contributes to genome segregation patterns and to the overall viral fitness in A(H1N1)pdm09 vaccine seeds.". Paper presented in OPTIONS X for the control of influenza Conference, 2019.
  8. Trigueiro-Louro, João. "Exploiting lineage-specificity of influenza B virus neuraminidase inhibitor natural susceptibility and selective pressure strength at resistance-associated sites.". Paper presented in OPTIONS X for the control of influenza Conference. Singapore, 2019.
  9. Trigueiro-Louro, João. "Unlocking the antiviral target potential of influenza A virus NS1 protein". Paper presented in OPTIONS X for the control of influenza Conference., 2019.
  10. Correia, Vanessa; Santos, Luís A.; Trigueiro-Louro, João; Abecasis, Ana; Rebelo-de-Andrade, Helena. "Victoria and Yamagata: Exploiting lineage-specificity of influenza B virus neuraminidase inhibitor natural susceptibility and selective pressure strength at resistance-associated sites". Paper presented in OPTIONS X for the Control of Influenza, 2019.
  11. Trigueiro-Louro, João. "Na rota dos descobrimentos de novos alvos antivirais contra a gripe - Mapeamento computacional do domínio efetor da proteína NS1.". Paper presented in V Congresso Nacional de Virologia, 2018.
  12. Trigueiro-Louro, João. "A cost-efficient solution: reagent comparison guide for neuraminidase inhibition assay". Paper presented in 19th Annual Meeting of the European Society for Clinical Virology, 2016.
Journal article
  1. Santos, Luís A.; Almeida, Filipe; Gíria, Marta; Trigueiro-Louro, João; Rebelo-de-Andrade, Helena. "Adaptive evolution of PB1 from influenza A(H1N1)pdm09 virus towards an enhanced fitness". Virology 578 (2023): 1-6. http://dx.doi.org/10.1016/j.virol.2022.11.003.
    10.1016/j.virol.2022.11.003
  2. Figueiredo-Nunes, Inês; Trigueiro-Louro, João; Rebelo-de-Andrade, Helena. "Exploring new antiviral targets for influenza and COVID-19: Mapping promising hot spots in viral RNA polymerases". Virology 578 (2023): 45-60. http://dx.doi.org/10.1016/j.virol.2022.11.001.
    10.1016/j.virol.2022.11.001
  3. Almeida, Filipe; Santos, Luís A.; Trigueiro-Louro, João M.; Rebelo-de-Andrade, Helena. "Optimization of A(H1N1)pdm09 vaccine seed viruses: The source of PB1 and HA vRNA as a major determinant for antigen yield". Virus Research 315 (2022): 198795. http://dx.doi.org/10.1016/j.virusres.2022.198795.
    10.1016/j.virusres.2022.198795
  4. David, Susana; Dorado, Guillermo; Duarte, Elsa L.; David-Bosne, Stephanie; Trigueiro-Louro, João; Rebelo-de-Andrade, Helena. "COVID-19: impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity". Immunogenetics 74 4 (2022): 381-407. http://dx.doi.org/10.1007/s00251-022-01261-w.
    10.1007/s00251-022-01261-w
  5. Trigueiro-Louro, João; Santos, Luís; Almeida, Filipe; Correia, Vanessa; Brito, Rui; Rebelo-de-Andrade, Helena. Corresponding author: Trigueiro-Louro, João. "NS1 protein as a novel anti-influenza target: Map-and-mutate antiviral rationale reveals new putative druggable hot spots with an important role on viral replication". Virology 565 (2022): 106-116. http://dx.doi.org/10.1016/j.virol.2021.11.001.
    10.1016/j.virol.2021.11.001
  6. Trigueiro-Louro, João; Correia, Vanessa; Figueiredo-Nunes, Inês; Gíria, Marta; Rebelo-de-Andrade, Helena. Corresponding author: Rebelo-de-Andrade, Helena. "Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike". Computational and Structural Biotechnology Journal 18 (2020): 2117-2131. https://doi.org/10.1016/j.csbj.2020.07.017.
    10.1016/j.csbj.2020.07.017
  7. Trigueiro-Louro, J.M.; Correia, V.; Santos, L.A.; Guedes, R.C.; Brito, R.M.M.; Rebelo-de-Andrade, H.. "To hit or not to hit: Large-scale sequence analysis and structure characterization of influenza A NS1 unlocks new antiviral target potential". Virology 535 (2019): 297-307. http://www.scopus.com/inward/record.url?eid=2-s2.0-85070696556&partnerID=MN8TOARS.
    10.1016/j.virol.2019.04.009
  8. Gíria, M.; Santos, L.; Louro, J.; Rebelo de Andrade, H.. "Reverse genetics vaccine seeds for influenza: Proof of concept in the source of PB1 as a determinant factor in virus growth and antigen yield". Virology 496 (2016): 21-27. http://www.scopus.com/inward/record.url?eid=2-s2.0-84969785437&partnerID=MN8TOARS.
    10.1016/j.virol.2016.05.015
Thesis / Dissertation
  1. "Conserved proteins of influenza virus and coronavirus as potential novel therapeutic targets". PhD, Universidade de Lisboa Faculdade de Farmácia, 2022. http://hdl.handle.net/10451/54912 repositorio.ulisboa.pt/handle/10451/54912.
  2. "Susceptibility of influenza a viruses to antiviral drugs : Targeting the NS1 dealer as a new anti-influenza virus strategy". Master, Universidade de Lisboa Faculdade de Farmácia, 2014. http://hdl.handle.net/10451/26845.
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2023/02/08 Exploring the NS5 protein of dengue virus as a novel antiviral target DURABLE annual meeting
DURABLE (Roterdam, Netherlands)
2020/10/04 Current status of vaccine development. COVID-19 panel Infection and Sepsis Symposium
Grupo de Investigação e Desenvolvimento em Infeção e Sepsis (Porto, Portugal)
2019/10/04 Tratamento e Medidas de Prevenção no quesito Gripe X Jornadas de Ciências da Saúde. X Jornadas de Ciências da Saúde
Instituto Universitário Egas Moniz (Almada, Portugal)
2019/04/10 Tratamento e Medidas de Prevenção no quesito Gripe X Jornadas de Ciências da Saúde
Instituto Universitário Egas Moniz (Lisboa, Portugal)
2017 Targeting a multitasking dealer. Exploring the NS1-p85ß interaction region as a potential influenza antiviral target. AstraZeneca Innovation Foundation Competition. iMED international Conference 9.0, Lisbon, Portugal MED international Conference 9.0, Lisbon, Portugal
(lisboa, Portugal)
2017 Influenza Reverse Genetic Vaccine Seeds: Unlock an optimized gene constellation for vaccine production. ipSC 9th iMed.ULisboa and 2nd i3du meeting. ipSC 9th iMed.ULisboa and 2nd i3du meeting.
(lisboa, Portugal)
2016 Synergistic effect of a PB1–NA gene constellation in Influenza A virus reassortants. iMED international Conference 8.0, Lisbon, CCB, Lisboa, Portugal MED international Conference 8.0, Lisbon, CCB, Lisboa, Portugal
(Lisboa, Portugal)
2014 Exploring of NS1-p85ß interaction region as a novel potential antiviral target”. AstraZeneca Innovation Foundation Competition. iMED International Conference 6.0, Rectory of NOVA University of Lisbon, Lisbon, Portugal. MED International Conference 6.0
(Lisboa, Portugal)

Supervision

Thesis Title
Role 		Degree Subject (Type)
Institution / Organization
2023 - Current Exploring proteins of dengue virus as novel antiviral targets
Co-supervisor
 Mestrado Integrado em Ciências Farmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2023 - Current Exploring the NS5 protein of dengue virus as a novel antiviral target
Co-supervisor
 Mestrado Integrado em Ciências Farmacêuticas (Scientific initiation)
2024 - 2024 Project I: Exploring the conservation of NS5 protein of dengue virus
Co-supervisor
 Ciências Farmacêuticas (Other)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2024 - 2024 Project II: Exploring the NS5 protein of dengue virus as a novel antiviral target
Co-supervisor
 Ciências Farmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2020/04/04 - 2020/12/01 Novas estratégias terapêuticas contra proteínas conservadas do vírus influenza - Final Monograph (tese final)
Co-supervisor
 Mestrado Integrado em Ciências Farmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2019/09/13 - 2020/01/25 ProjectII: Influenza A and B virus NS1 protein as a potential therapeutic target
Co-supervisor
 Mestrado Integrado em Ciências Farmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal
2018/10/04 - 2019/06/06 Project I: Influenza B virus NS1 protein as a potential therapeutic target
Co-supervisor of Inês Figueiredo Nunes
 Mestrado Integrado em Ciências Farmacêuticas (Master)
Universidade de Lisboa Faculdade de Farmácia, Portugal

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2014/05/28 - Current A non-infectious transfection system for expression of a non-human neuraminidase Virus Reference Department (VRD) Seminar
2014/05/28 - Current Characterization of influenza A(H1N1)pdm09 viruses in original material from portuguese clinical samples Virus Reference Department (VRD) Seminar
2024 - 2024 1st year DURABLE consortium: Delivering a Unified Research Alliance of Biomedical and public health Laboratories against Epidemics to support Health Emergency Preparedness and Response (HERA). Rotterdam, Netherlands
Congress
 1st year DURABLE consortium
2024 - 2024 1st European DURABLE consortium School (online): Research Management During Outbreaks (2024).
Meeting
 - 1st European DURABLE consortium School
2023/05 - 2023/05 Apresentação no 10º Congresso & VI Congresso Nacional de Virologia. Coimbra, Portugal. Abordagem clínica e terapêutica da gripe: Lições aprendidas num centenário de epidemias e pandemias. Pandemias na Era da Globalização.
Congress
 10º Congresso & VI Congresso Nacional de Virologia

Consulting

Activity description Institution / Organization
2024 - 2024 Bayer Consultant - Antifungal therapies and resistance Bayer Portugal SA, Portugal
2022 - 2022 Webinar Pfizer - Antivirais Orais para o tratamento da COVID-19 Pfizer Portugal, Portugal
2020/04/01 - 2020/10/31 Volunteer Consultant in Virology General Directorate of Health, Lisbon Portugal (COVID-19 Task Force) SARS-CoV-2 virology and Public Health control measures for COVID-19 Direção-Geral da Saúde, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2024/12 - Current 19º Curso de Pós-Graduação em Doenças infecciosas - Gripe - Abordagem virológica, clínica e terapêutica 19º Curso de Pós-Graduação em Doenças infecciosas (Pós-Graduação)
2021/04/16 - 2025/04/16 Bioinformatic tools for the identification of emerging therapeutic targets (early drug discovery) Curso: Infeções Emergentes de Etiologia Vírica. Mestrado em Ciências Biofarmacêuticas. Lisboa (Mestrado) Universidade de Lisboa Faculdade de Farmácia, Portugal

Evaluation committee

Activity description
Role 		Institution / Organization Funding entity
2024 - 2024 Jury member at the AstraZeneca Scientific Medical Competition (2024) – Innovate Competition – iMED International Conference 16.0, Lisbon, Portugal.
Evaluator

Journal scientific committee

Journal title (ISSN) Publisher
2024 - Current Virology Journal
2023 - Current BMC Pulmonary
2021 - 2021 BMC Bioinformatics
Distinctions

Award

2020 Young Scientist Award - Scientific communication at Seventh ESWI Influenza and COVID-19

Other distinction

2017 Ph.D. fellowship - FCT PD/BD/128402/2017 (PhD Programme i3DU)
Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal
2014 3rd place for the best poster presentation in the iMED International Conference 6.0 with an original Basic Research project entitled “Exploring of NS1 - p85ß interaction region as a novel potential antiviral target”